<DOC>
	<DOCNO>NCT01129739</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy mesenchymal stem cell ( MSCs ) derive human umbilical cord/placenta dose 1.0E+6 MSC/kg subject refractory anemia ( RA ) refractory anemia ring sideroblast ( RARS ) myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>Safety Efficacy Study Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells Treat Myelodysplastic Syndromes</brief_title>
	<detailed_description>Myelodysplastic syndrome bone marrow stem cell disorder result disorderly ineffective hematopoiesis . MDS characterize variable degree cytopenias ( anemia , neutropenia , thrombocytopenia ) risk transformation leukemia . To date treatment MDS unsatisfactory : chemotherapy limit role management leukemic progression ; autologous stem cell transplantation prolong relapse-free survival stem cell transplantation poorly tolerate old individual . Some MDS patient show respond wide variety immunosuppressive agent range corticosteroid CsA antithymocyte globulin ( ATG ) . However , overall response rate le 30 % . In fact , treatment appear change natural history MDS . The management MDS patient therefore remain improved . Human MSCs isolate Wharton 's jelly umbilical cord/placenta show immunosuppressive , stimulating hematopoiesis tissue repair property . This study evaluate safety effectiveness MSC transplant MDS patient . This study last 3 year . Participants randomly assign receive either MSC transplant ( Group 1 ) CsA therapy alone ( Group 2 ) . Patients undergo MSC transplant start study ( define Day 0 ) . After 3 month , patient receive second MSC transplantation one respond well treatment . After 3 , 6 12 month first transplantation , patient evaluate .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>1 . Patient age 18~80 year old plan infuse MSCs . 2 . Histologically document cytologically confirm diagnosis MDS WHO classification MDSRA MDSRARS . 3 . Patients must ECOG 0~2 . 4 . No moderate sever organ dysfunction : Ejection fraction &gt; 45 % ; Creatinine &lt; 176 mmol/L . 5 . No active severe viral fungus infection . 6 . Each patient must sign write informed consent . 1 . Psychiatric condition would limit informed consent . 2 . HIV positive 3 . Positive Pregnancy Test 4 . Patient enrol another clinical trial study within last 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Bone Marrow Disease</keyword>
	<keyword>MDS-RA</keyword>
	<keyword>MDS-RARS</keyword>
	<keyword>Umbilical Cord/placenta-Derived MSC</keyword>
	<keyword>Transplant</keyword>
</DOC>